T CELL SUBSIDIARY NAMES CEO ...William Gelb has been named chairman and chief executiveofficer of T Cell Diagnostics Inc., the Cambridge, Mass.,subsidiary of T Cell Sciences Inc. (NASDAQ:TCEL). Gelb had beenpresident and CEO of Landec Labs Inc. David Corbet remainspresident and chief operating officer of Diagnostics, whichdevelops products for monitoring immune system disorders.
Michael A. Appelbaum, formerly vice president and chieffinancial officer of Hatco Corp., has been named vice presidentand CFO of Medarex Inc. (NASDAQ:MEDX, MEDXW), a Princeton,N.J., developer of treatments for AIDS, cancer andcardiovascular disease.
BioCAD Corp., a Mountain View, Calif., developer of computer-aided drug discovery systems, has named Peter W. Sprague vicepresident of technical support. He was previously an executivedirector of chemistry at Bristol-Myers Squibb Co.
Jennifer Pierce has been named manager of investor relationsof Genzyme Corp. (NASDAQ:GENZ) in Cambridge, Mass. DonnaLaVoie has been named manager of public relations at thecompany, which develops biotherapeutics, diagnostics andpharmaceuticals.
Jordan U. Gutterman, chairman of the department of clinicalimmunology and biological therapy at the M.D. Anderson CancerCenter at the University of Texas, Houston, has been appointedto the scientific advisory board of Enzytech Inc., a Cambridge,Mass., developer of protein and peptide delivery systems.
GeorgeAP. Vlasuk, former associate director of hematologicresearch at Merck Sharp & Dohme Research Laboratories, willbecome director of molecular pharmacology at CorvasInternational Inc., a San Diego developer of vascular disease-treating pharmaceuticals.
Harvey S. Sadow, retired chairman, president and chiefexecutive officer of Boehringer Ingelheim Corp., has beennamed to the board of TargeTech Inc., a Meriden, Conn.,developer of injectable gene therapies.
Gustav A. Christensen, formerly president and chief executiveofficer of ImmuLogic Pharmaceutical Corp., has been namedchairman of Alpha-Beta Technology, a Worchester, Mass.,developer of carbohydrate-based health care products.
Kenneth J. Collins, former vice president and chief financialofficer of Synergen Inc. (NASDAQ: SYGN), has become executivevice president of finance and administration for Cytel Corp., aSan Diego developer of small molecule therapeutics forautoimmune diseases. Thomas M. Glenn, Ph.D., previouslyassociate vice chancellor for health affairs at Duke UniversityMedical Center, has become Cytel's vice president ofpharmaceutical development.
Agouron Pharmaceuticals Inc. (NASDAQ:AGPH), a La Jolla,Calif., developer of rational drug treatments for cancer andAIDS, has appointed Steven S. Cowell, former vice presidentand controller of Cetus Corp. to the position of vice presidentand chief financial officer. -- Jeff Hutkoff
(c) 1997 American Health Consultants. All rights reserved.